Ceapro Inc. (CZO.V)
| Previous Close | 0.7200 |
| Open | 0.7000 |
| Bid | 0.7000 x 0 |
| Ask | 0.7200 x 0 |
| Day's Range | 0.7000 - 0.7000 |
| 52 Week Range | 0.4000 - 0.8200 |
| Volume | |
| Avg. Volume | 22,412 |
| Market Cap | 54.753M |
| Beta (5Y Monthly) | 1.48 |
| PE Ratio (TTM) | 10.00 |
| EPS (TTM) | 0.0700 |
| Earnings Date | Apr 11, 2023 - Apr 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023.
- GlobeNewswire
Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Wednesday, January 18th at 3:00 PM ETEDMONTON, Alberta, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, M.Sc., MBA, President and Chief Executive Officer of Ceapro, will present at the Virtual Investor 2023 Companies to Watch Event on Wedne
- GlobeNewswire
Ceapro Announces Grant of Stock Options
EDMONTON, Alberta, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the granting of stock options (“options”) to employees, officers and directors of the Company. Options to purchase 740,000 common shares were granted pursuant to the Company’s Stock Option Plan, with an exercise pri
